177Lu-DOTA-EB-TATE for Neuroendocrine Tumors
Phase-Based Progress Estimates
Effectiveness
Safety
Memorial Sloan Kettering Cancer Center, New York, NY
Neuroendocrine Tumors
177Lu-DOTA-EB-TATE - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial is to test a new treatment for a rare cancer. It will study how well the treatment works and what side effects it may have. The trial medication, 177Lu-DOTA-EB-TATE, is used to treat neuroendocrine tumors and is provided free of charge. This treatment has previously been approved by the FDA for a different condition. In this trial, there will be no patients receiving a placebo.
Treatment Effectiveness
Effectiveness Progress
Other trials for Neuroendocrine Tumors
Study Objectives
3 Primary · 2 Secondary · Reporting Duration: 16-17 months
16-17 months
To determine if the maximum tolerated dose is among the explored doses of 50, 100 and 150 mCi.
To evaluate dosimetry levels in patients following 2 cycles of 177Lu-DOTA-EB-TATE.
To evaluate the differential safety of 177Lu-DOTA-EB-TATE, expressed as the number of patients with treatment-related adverse events following 177Lu-DOTA-EB-TATE.
To evaluate the safety of 177Lu-DOTA-EB-TATE assessed from the number of patients with treatment-related adverse events.
To identify the dose-limiting toxicities (DLTs) of escalating doses of 177Lu-DOTA-EB-TATE up to 150 mCi.
Trial Safety
Safety Progress
Other trials for Neuroendocrine Tumors
Trial Design
1 Treatment Group
Peptide Receptor Radionucleotide Therapy (PRRT)
1 of 1
Experimental Treatment
9 Total Participants · 1 Treatment Group
Primary Treatment: 177Lu-DOTA-EB-TATE · No Placebo Group · Phase 1
Peptide Receptor Radionucleotide Therapy (PRRT)Experimental Group · 2 Interventions: 177Lu-DOTA-EB-TATE, Amino Acid Solution · Intervention Types: Drug, Other
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 16-17 months
Closest Location: Memorial Sloan Kettering Cancer Center · New York, NY
2011First Recorded Clinical Trial
20 TrialsResearching Neuroendocrine Tumors
968 CompletedClinical Trials
Who is running the clinical trial?
Molecular Targeting Technologies, Inc.Lead Sponsor
2 Previous Clinical Trials
72 Total Patients Enrolled
ClinSmartIndustry Sponsor
1 Previous Clinical Trials
18 Total Patients Enrolled
Lisa Bodei, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
10 Total Patients Enrolled
1 Trials studying Neuroendocrine Tumors
10 Patients Enrolled for Neuroendocrine Tumors
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:Previous local therapy (e.g.
You have histologically proven or cytologically confirmed, inoperable, GEP-NETs.
You have neuroendocrine tumors (NETs) of grade 1, 2 and 3 according to WHO 2017 classification.
You have measurable disease as defined by RECIST version 1.1.
You have at least 1 lesion with SUV greater than normal liver in at least 1 lesion.
You have a creatinine clearance > 60 mL/min.
You have a Karnofsky performance status of 70% or more.
You are of childbearing potential and you and your partner agree to use adequate contraception prior to study entry and for the duration of study participation, including follow-up (7 months after the last dose of study drug for women and 4 months for men).
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments